Elafibranor safe, effective in patients with PBC

Patients with primary biliary cholangitis treated with elafibranor experienced lowered alkaline phosphatase after 12 weeks, according to study results.“These promising findings along with existing safety data derived from past clinical trials suggest elafibranor is a promising development candidate as a potential novel treatment for patients with PBC,” Jörn M. Schattenberg, MD, from University Medical Centre Mainz in Germany, said in a press release. “Regulatory authorities know the disease well and there remains an important unmet need to be addressed as many patientsRead More

Share on facebook
Share on twitter
Share on linkedin